APA (7th ed.) Citation

Peter G. Rose, Myra Feldman, Iwona Podzielinski, Aaron P. Petty, & Roberto Vargas. (2023). Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series. Elsevier.

Chicago Style (17th ed.) Citation

Peter G. Rose, Myra Feldman, Iwona Podzielinski, Aaron P. Petty, and Roberto Vargas. Activity of Pembrolizumab and Lenvatinib in Mismatch Repair Deficient (dMMR) Endometrial Cancer Patients Who Have Failed Pembrolizumab Monotherapy: A Case Series. Elsevier, 2023.

MLA (9th ed.) Citation

Peter G. Rose, et al. Activity of Pembrolizumab and Lenvatinib in Mismatch Repair Deficient (dMMR) Endometrial Cancer Patients Who Have Failed Pembrolizumab Monotherapy: A Case Series. Elsevier, 2023.